MoneyWorks4Me

Alivus Life Sciences gets nod to acquire 76% stake in IQGEN-X Pharma

19 Aug 2026 Evaluate

Alivus Life Sciences’ board has approved the share purchase agreement to acquire 76% stake in IQGEN-X Pharma for an aggregate consideration of approximately Rs 9.12 crore subject to adjustment as per Share purchase agreement. 

IQGEN-X Pharma provides a wider spectrum for the company to offer a complete end-to-end solution to its customers in both API and CDMO space. The Board of Directors of the company at its meeting held on August 18, 2026, approved the same. 

Alivus Life Sciences (formerly Glenmark Life Sciences) is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. 


Alivus Life Sciences Share Price

1348.60 -21.60 (-1.58%)
21-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1900.90
Dr. Reddys Labs. 1175.00
Cipla 1426.20
Lupin 2193.00
Zydus Lifesciences 1120.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: